Current and Future Treatments of Vascular Cognitive Impairment

HomeStrokeVol. 55, No. 4Current and Future Treatments of Vascular Cognitive Impairment No AccessReview ArticleRequest AccessFull TextAboutView Full TextView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toNo AccessReview ArticleRequest AccessFull TextCurrent and Future Treatments of Vascular Cognitive Impairment Bonaventure Yiu Ming Ip, Ho Ko, Bonnie Yin Ka Lam, Lisa Wing Chi Au, Alexander Yuk Lun Lau, Junzhe Huang, Andrew John Kwok, Xinyi Leng, Yuan Cai, Thomas Wai Hong Leung and Vincent Chung Tong Mok Bonaventure Yiu Ming IpBonaventure Yiu Ming Ip https://orcid.org/0000-0002-1619-4992 Division of Neurology, Department of Medicine and Therapeutics (B.Y.M.I., H.K., B.Y.K.L., L.W.C.A., A.Y.L.L., J.H., A.J.K., X.L., C.Y., T.W.H.L., V.C.T.M.), Faculty of Medicine, The Chinese University of Hong Kong. Li Ka Shing Institute of Health Sciences (B.Y.M.I., H.K., B.Y.K.L., L.W.C.A., J.H., A.J.K., X.L., C.Y., T.W.H.L., V.C.T.M.), Faculty of Medicine, The Chinese University of Hong Kong. Margaret K. L. Cheung Research Centre for Management of Parkinsonism (B.Y.M.I., H.K., B.Y.K.L., L.W.C.A., J.H., A.J.K., C.Y., V.C.T.M.), Faculty of Medicine, The Chinese University of Hong Kong. Lau Tat-Chuen Research Centre of Brain Degenerative Diseases in Chinese (B.Y.M.I., H.K., B.Y.K.L., L.W.C.A., A.Y.L.L., J.H., A.J.K., C.Y., V.C.T.M.), Faculty of Medicine, The Chinese University of Hong Kong. Gerald Choa Neuroscience Institute, The Chinese University of Hong Kong (B.Y.M.I., H.K., B.Y.K.L., L.W.C.A., J.H., A.J.K., C.Y., V.C.T.M.). Kwok Tak Seng Centre for Stroke Research and Intervention, Hong Kong SAR, China (B.Y.M.I., X.L., T.W.H.L.). , Ho KoHo Ko Division of Neurology, Department of Medicine and Therapeutics (B.Y.M.I., H.K., B.Y.K.L., L.W.C.A., A.Y.L.L., J.H., A.J.K., X.L., C.Y., T.W.H.L., V.C.T.M.), Faculty of Medicine, The Chinese University of Hong Kong. Li Ka Shing Institute of Health Sciences (B.Y.M.I., H.K., B.Y.K.L., L.W.C.A., J.H., A.J.K., X.L., C.Y., T.W.H.L., V.C.T.M.), Faculty of Medicine, The Chinese University of Hong Kong. Margaret K. L. Cheung Research Centre for Management of Parkinsonism (B.Y.M.I., H.K., B.Y.K.L., L.W.C.A., J.H., A.J.K., C.Y., V.C.T.M.), Faculty of Medicine, The Chinese University of Hong Kong. Lau Tat-Chuen Research Centre of Brain Degenerative Diseases in Chinese (B.Y.M.I., H.K., B.Y.K.L., L.W.C.A., A.Y.L.L., J.H., A.J.K., C.Y., V.C.T.M.), Faculty of Medicine, The Chinese University of Hong Kong. Gerald Choa Neuroscience Institute, The Chinese University of Hong Kong (B.Y.M.I., H.K., B.Y.K.L., L.W.C.A., J.H., A.J.K., C.Y., V.C.T.M.). , Bonnie Yin Ka LamBonnie Yin Ka Lam https://orcid.org/0000-0002-1656-2433 Division of Neurology, Department of Medicine and Therapeutics (B.Y.M.I., H.K., B.Y.K.L., L.W.C.A., A.Y.L.L., J.H., A.J.K., X.L., C.Y., T.W.H.L., V.C.T.M.), Faculty of Medicine, The Chinese University of Hong Kong. Li Ka Shing Institute of Health Sciences (B.Y.M.I., H.K., B.Y.K.L., L.W.C.A., J.H., A.J.K., X.L., C.Y., T.W.H.L., V.C.T.M.), Faculty of Medicine, The Chinese University of Hong Kong. Margaret K. L. Cheung Research Centre for Management of Parkinsonism (B.Y.M.I., H.K., B.Y.K.L., L.W.C.A., J.H., A.J.K., C.Y., V.C.T.M.), Faculty of Medicine, The Chinese University of Hong Kong. Lau Tat-Chuen Research Centre of Brain Degenerative Diseases in Chinese (B.Y.M.I., H.K., B.Y.K.L., L.W.C.A., A.Y.L.L., J.H., A.J.K., C.Y., V.C.T.M.), Faculty of Medicine, The Chinese University of Hong Kong. Gerald Choa Neuroscience Institute, The Chinese University of Hong Kong (B.Y.M.I., H.K., B.Y.K.L., L.W.C.A., J.H., A.J.K., C.Y., V.C.T.M.). , Lisa Wing Chi AuLisa Wing Chi Au https://orcid.org/0000-0003-0711-3932 Division of Neurology, Department of Medicine and Therapeutics (B.Y.M.I., H.K., B.Y.K.L., L.W.C.A., A.Y.L.L., J.H., A.J.K., X.L., C.Y., T.W.H.L., V.C.T.M.), Faculty of Medicine, The Chinese University of Hong Kong. Li Ka Shing Institute of Health Sciences (B.Y.M.I., H.K., B.Y.K.L., L.W.C.A., J.H., A.J.K., X.L., C.Y., T.W.H.L., V.C.T.M.), Faculty of Medicine, The Chinese University of Hong Kong. Margaret K. L. Cheung Research Centre for Management of Parkinsonism (B.Y.M.I., H.K., B.Y.K.L., L.W.C.A., J.H., A.J.K., C.Y., V.C.T.M.), Faculty of Medicine, The Chinese University of Hong Kong. Lau Tat-Chuen Research Centre of Brain Degenerative Diseases in Chinese (B.Y.M.I., H.K., B.Y.K.L., L.W.C.A., A.Y.L.L., J.H., A.J.K., C.Y., V.C.T.M.), Faculty of Medicine, The Chinese University of Hong Kong. Gerald Choa Neuroscience Institute, The Chinese University of Hong Kong (B.Y.M.I., H.K., B.Y.K.L., L.W.C.A., J.H., A.J.K., C.Y., V.C.T.M.). , Alexander Yuk Lun LauAlexander Yuk Lun Lau https://orcid.org/0000-0002-5933-9290 Division of Neurology, Department of Medicine and Therapeutics (B.Y.M.I., H.K., B.Y.K.L., L.W.C.A., A.Y.L.L., J.H., A.J.K., X.L., C.Y., T.W.H.L., V.C.T.M.), Faculty of Medicine, The Chinese University of Hong Kong. Margaret K. L. Cheung Research Centre for Management of Parkinsonism (B.Y.M.I., H.K., B.Y.K.L., L.W.C.A., J.H., A.J.K., C.Y., V.C.T.M.), Faculty of Medicine, The Chinese University of Hong Kong. Lau Tat-Chuen Research Centre of Brain Degenerative Diseases in Chinese (B.Y.M.I., H.K., B.Y.K.L., L.W.C.A., A.Y.L.L., J.H., A.J.K., C.Y., V.C.T.M.), Faculty of Medicine, The Chinese University of Hong Kong. , Junzhe HuangJunzhe Huang https://orcid.org/0000-0003-4859-9385 Division of Neurology, Department of Medicine and Therapeutics (B.Y.M.I., H.K., B.Y.K.L., L.W.C.A., A.Y.L.L., J.H., A.J.K., X.L., C.Y., T.W.H.L., V.C.T.M.), Faculty of Medicine, The Chinese University of Hong Kong. Li Ka Shing Institute of Health Sciences (B.Y.M.I., H.K., B.Y.K.L., L.W.C.A., J.H., A.J.K., X.L., C.Y., T.W.H.L., V.C.T.M.), Faculty of Medicine, The Chinese University of Hong Kong. Margaret K. L. Cheung Research Centre for Management of Parkinsonism (B.Y.M.I., H.K., B.Y.K.L., L.W.C.A., J.H., A.J.K., C.Y., V.C.T.M.), Faculty of Medicine, The Chinese University of Hong Kong. Lau Tat-Chuen Research Centre of Brain Degenerative Diseases in Chinese (B.Y.M.I., H.K., B.Y.K.L., L.W.C.A., A.Y.L.L., J.H., A.J.K., C.Y., V.C.T.M.), Faculty of Medicine, The Chinese University of Hong Kong. Gerald Choa Neuroscience Institute, The Chinese University of Hong Kong (B.Y.M.I., H.K., B.Y.K.L., L.W.C.A., J.H., A.J.K., C.Y., V.C.T.M.). , Andrew John KwokAndrew John Kwok https://orcid.org/0000-0001-8928-5054 Division of Neurology, Department of Medicine and Therapeutics (B.Y.M.I., H.K., B.Y.K.L., L.W.C.A., A.Y.L.L., J.H., A.J.K., X.L., C.Y., T.W.H.L., V.C.T.M.), Faculty of Medicine, The Chinese University of Hong Kong. Li Ka Shing Institute of Health Sciences (B.Y.M.I., H.K., B.Y.K.L., L.W.C.A., J.H., A.J.K., X.L., C.Y., T.W.H.L., V.C.T.M.), Faculty of Medicine, The Chinese University of Hong Kong. Lau Tat-Chuen Research Centre of Brain Degenerative Diseases in Chinese (B.Y.M.I., H.K., B.Y.K.L., L.W.C.A., A.Y.L.L., J.H., A.J.K., C.Y., V.C.T.M.), Faculty of Medicine, The Chinese University of Hong Kong. Gerald Choa Neuroscience Institute, The Chinese University of Hong Kong (B.Y.M.I., H.K., B.Y.K.L., L.W.C.A., J.H., A.J.K., C.Y., V.C.T.M.). , Xinyi LengXinyi Leng https://orcid.org/0000-0001-7300-6647 Division of Neurology, Department of Medicine and Therapeutics (B.Y.M.I., H.K., B.Y.K.L., L.W.C.A., A.Y.L.L., J.H., A.J.K., X.L., C.Y., T.W.H.L., V.C.T.M.), Faculty of Medicine, The Chinese University of Hong Kong. Li Ka Shing Institute of Health Sciences (B.Y.M.I., H.K., B.Y.K.L., L.W.C.A., J.H., A.J.K., X.L., C.Y., T.W.H.L., V.C.T.M.), Faculty of Medicine, The Chinese University of Hong Kong. Kwok Tak Seng Centre for Stroke Research and Intervention, Hong Kong SAR, China (B.Y.M.I., X.L., T.W.H.L.). , Yuan CaiYuan Cai Division of Neurology, Department of Medicine and Therapeutics (B.Y.M.I., H.K., B.Y.K.L., L.W.C.A., A.Y.L.L., J.H., A.J.K., X.L., C.Y., T.W.H.L., V.C.T.M.), Faculty of Medicine, The Chinese University of Hong Kong. Li Ka Shing Institute of Health Sciences (B.Y.M.I., H.K., B.Y.K.L., L.W.C.A., J.H., A.J.K., X.L., C.Y., T.W.H.L., V.C.T.M.), Faculty of Medicine, The Chinese University of Hong Kong. Margaret K. L. Cheung Research Centre for Management of Parkinsonism (B.Y.M.I., H.K., B.Y.K.L., L.W.C.A., J.H., A.J.K., C.Y., V.C.T.M.), Faculty of Medicine, The Chinese University of Hong Kong. Lau Tat-Chuen Research Centre of Brain Degenerative Diseases in Chinese (B.Y.M.I., H.K., B.Y.K.L., L.W.C.A., A.Y.L.L., J.H., A.J.K., C.Y., V.C.T.M.), Faculty of Medicine, The Chinese University of Hong Kong. Gerald Choa Neuroscience Institute, The Chinese University of Hong Kong (B.Y.M.I., H.K., B.Y.K.L., L.W.C.A., J.H., A.J.K., C.Y., V.C.T.M.). , Thomas Wai Hong LeungThomas Wai Hong Leung https://orcid.org/0000-0001-8193-0709 Division of Neurology, Department of Medicine and Therapeutics (B.Y.M.I., H.K., B.Y.K.L., L.W.C.A., A.Y.L.L., J.H., A.J.K., X.L., C.Y., T.W.H.L., V.C.T.M.), Faculty of Medicine, The Chinese University of Hong Kong. Li Ka Shing Institute of Health Sciences (B.Y.M.I., H.K., B.Y.K.L., L.W.C.A., J.H., A.J.K., X.L., C.Y., T.W.H.L., V.C.T.M.), Faculty of Medicine, The Chinese University of Hong Kong. Kwok Tak Seng Centre for Stroke Research and Intervention, Hong Kong SAR, China (B.Y.M.I., X.L., T.W.H.L.). and Vincent Chung Tong MokVincent Chung Tong Mok Correspondence to: Vincent Chung Tong Mok, MD, Department of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Prince of Wales Hospital, 30-32, Ngan Shing St, New Territories, Hong Kong SAR, China. Email E-mail Address: [email protected] https://orcid.org/0000-0002-8102-8835 Division of Neurology, Department of Medicine and Therapeutics (B.Y.M.I., H.K., B.Y.K.L., L.W.C.A., A.Y.L.L., J.H., A.J.K., X.L., C.Y., T.W.H.L., V.C.T.M.), Faculty of Medicine, The Chinese University of Hong Kong. Li Ka Shing Institute of Health Sciences (B.Y.M.I., H.K., B.Y.K.L., L.W.C.A., J.H., A.J.K., X.L., C.Y., T.W.H.L., V.C.T.M.), Faculty of Medicine, The Chinese University of Hong Kong. Margaret K. L. Cheung Research Centre for Management of Parkinsonism (B.Y.M.I., H.K., B.Y.K.L., L.W.C.A., J.H., A.J.K., C.Y., V.C.T.M.), Faculty of Medicine, The Chinese University of Hong Kong. Lau Tat-Chuen Research Centre of Brain Degenerative Diseases in Chinese (B.Y.M.I., H.K., B.Y.K.L., L.W.C.A., A.Y.L.L., J.H., A.J.K., C.Y., V.C.T.M.), Faculty of Medicine, The Chinese University of Hong Kong. Gerald Choa Neuroscience Institute, The Chinese University of Hong Kong (B.Y.M.I., H.K., B.Y.K.L., L.W.C.A., J.H., A.J.K., C.Y., V.C.T.M.). Originally published25 Mar 2024https://doi.org/10.1161/STROKEAHA.123.044174Stroke. 2024;55:822–839is companion ofPrevention of Vascular Contributions to Cognitive Impairment and Dementia: The Role of Physical Activity and ExerciseImaging Biomarkers of VCI: A Focused UpdateSoluble Biomarkers of Cerebrovascular PathologiesIntroduction to Focused Update Vascular Cognitive Impairment and Dementia: Better Diagnosis, More Avenues for PreventionFootnotesFor Sources of Funding and Disclosures, see page 832.Correspondence to: Vincent Chung Tong Mok, MD, Department of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Prince of Wales Hospital, 30-32, Ngan Shing St, New Territories, Hong Kong SAR, China. Email vctmok@cuhk.edu.hkREFERENCES1. Gorelick PB, Scuteri A, Black SE, Decarli C, Greenberg SM, Iadecola C, Launer LJ, Laurent S, Lopez OL, Nyenhuis D, et al; American Heart Association Stroke Council, Council on Epidemiology and Prevention, Council on Cardiovascular Nursing, Council on Cardiovascular Radiology and Intervention, and Council on Cardiovascular Surgery and Anesthesia. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association.Stroke. 2011; 42:2672–2713. doi: 10.1161/STR.0b013e3182299496LinkGoogle Scholar2. Schneider JA, Wilson RS, Cochran EJ, Bienias JL, Arnold SE, Evans DA, Bennett DA. Relation of cerebral infarctions to dementia and cognitive function in older persons.Neurology. 2003; 60:1082–1088. doi: 10.1212/01.wnl.0000055863.87435.b2CrossrefMedlineGoogle Scholar3. Makin SD, Turpin S, Dennis MS, Wardlaw JM. Cognitive impairment after lacunar stroke: systematic review and meta-analysis of incidence, prevalence and comparison with other stroke subtypes.J Neurol Neurosurg Psychiatry. 2013; 84:893–900. doi: 10.1136/jnnp-2012-303645CrossrefMedlineGoogle Scholar4. Weaver NA, Kuijf HJ, Aben HP, Abrigo J, Bae HJ, Barbay M, Best JG, Bordet R, Chappell FM, Chen C, et al. Strategic infarct locations for post-stroke cognitive impairment: a pooled analysis of individual patient data from 12 acute ischaemic stroke cohorts.Lancet Neurol. 2021; 20:448–459. doi: 10.1016/S1474-4422(21)00060-0CrossrefMedlineGoogle Scholar5. Wardlaw JM, Smith C, Dichgans M. Small vessel disease: mechanisms and clinical implications.Lancet Neurol. 2019; 18:684–696. doi: 10.1016/S1474-4422(19)30079-1CrossrefMedlineGoogle Scholar6. Mok VC, Wong A, Lam WW, Fan YH, Tang WK, Kwok T, Hui AC, Wong KS. Cognitive impairment and functional outcome after stroke associated with small vessel disease.J Neurol Neurosurg Psychiatry. 2004; 75:560–566. doi: 10.1136/jnnp.2003.015107CrossrefMedlineGoogle Scholar7. Zhang CE, Wong SM, Uiterwijk R, Backes WH, Jansen JFA, Jeukens C, van Oostenbrugge RJ, Staals J. Blood-brain barrier leakage in relation to white matter hyperintensity volume and cognition in small vessel disease and normal aging.Brain Imaging Behav. 2019; 13:389–395. doi: 10.1007/s11682-018-9855-7CrossrefGoogle Scholar8. Wardlaw JM, Makin SJ, Valdés Hernández MC, Armitage PA, Heye AK, Chappell FM, Muñoz-Maniega S, Sakka E, Shuler K, Dennis MS, et al. Blood-brain barrier failure as a core mechanism in cerebral small vessel disease and dementia: evidence from a cohort study.Alzheimers Dement. 2017; 13:634–643. doi: 10.1016/j.jalz.2016.09.006CrossrefGoogle Scholar9. Rost NS, Brodtmann A, Pase MP, van Veluw SJ, Biffi A, Duering M, Hinman JD, Dichgans M. Post-stroke cognitive impairment and dementia.Circ Res. 2022; 130:1252–1271. doi: 10.1161/CIRCRESAHA.122.319951LinkGoogle Scholar10. Sexton E, McLoughlin A, Williams DJ, Merriman NA, Donnelly N, Rohde D, Hickey A, Wren MA, Bennett K. Systematic review and meta-analysis of the prevalence of cognitive impairment no dementia in the first year post-stroke.Eur Stroke J. 2019; 4:160–171. doi: 10.1177/2396987318825484CrossrefMedlineGoogle Scholar11. Craig L, Hoo ZL, Yan TZ, Wardlaw J, Quinn TJ. Prevalence of dementia in ischaemic or mixed stroke populations: systematic review and meta-analysis.J Neurol Neurosurg Psychiatry. 2022; 93:180–187. doi: 10.1136/jnnp-2020-325796CrossrefGoogle Scholar12. Zhao L, Biesbroek JM, Shi L, Liu W, Kuijf HJ, Chu WW, Abrigo JM, Lee RK, Leung TW, Lau AY, et al. Strategic infarct location for post-stroke cognitive impairment: a multivariate lesion-symptom mapping study.J Cereb Blood Flow Metab. 2018; 38:1299–1311. doi: 10.1177/0271678X17728162CrossrefMedlineGoogle Scholar13. van der Flier WM, Skoog I, Schneider JA, Pantoni L, Mok V, Chen CLH, Scheltens P. Vascular cognitive impairment.Nat Rev Dis Primers. 2018; 4:18003. doi: 10.1038/nrdp.2018.3CrossrefMedlineGoogle Scholar14. Ismail M, Mok VC, Wong A, Au L, Yiu B, Wang Z, Chu WC, Chan AY, Fan FS, Ma SH, et al. Risk factors for delayed-onset dementia after stroke or transient ischemic attack-a five-year longitudinal cohort study.Int J Stroke. 2022; 17:517–525. doi: 10.1177/17474930211026519CrossrefGoogle Scholar15. Pendlebury ST, Rothwell PM. Prevalence, incidence, and factors associated with pre-stroke and post-stroke dementia: a systematic review and meta-analysis.Lancet Neurol. 2009; 8:1006–1018. doi: 10.1016/S1474-4422(09)70236-4CrossrefMedlineGoogle Scholar16. Mok VC, Lam BY, Wong A, Ko H, Markus HS, Wong LK. Early-onset and delayed-onset poststroke dementia - revisiting the mechanisms.Nat Rev Neurol. 2017; 13:148–159. doi: 10.1038/nrneurol.2017.16CrossrefMedlineGoogle Scholar17. Pendlebury ST, Rothwell PM; Oxford Vascular Study. Incidence and prevalence of dementia associated with transient ischaemic attack and stroke: analysis of the population-based Oxford Vascular Study.Lancet Neurol. 2019; 18:248–258. doi: 10.1016/S1474-4422(18)30442-3CrossrefMedlineGoogle Scholar18. Mok VCT, Lam BYK, Wang Z, Liu W, Au L, Leung EYL, Chen S, Yang J, Chu WCW, Lau AYL, et al. Delayed-onset dementia after stroke or transient ischemic attack.Alzheimers Dement. 2016; 12:1167–1176. doi: 10.1016/j.jalz.2016.05.007CrossrefMedlineGoogle Scholar19. Sandvig HV, Aam S, Alme KN, Askim T, Beyer MK, Ellekjær H, Ihle-Hansen H, Lydersen S, Mollnes TE, Munthe-Kaas R, et al. Plasma inflammatory biomarkers are associated with poststroke cognitive impairment: the Nor-COAST study.Stroke. 2023; 54:1303–1311. doi: 10.1161/STROKEAHA.122.041965LinkGoogle Scholar20. Lam BYK, Yiu B, Ampil E, Chen CL, Dikot Y, Dominguez JC, Ganeshbhai PV, Hilal S, Kandiah N, Kim S, et al. High burden of cerebral white matter lesion in 9 Asian cities.Sci Rep. 2021; 11:11587. doi: 10.1038/s41598-021-90746-xCrossrefGoogle Scholar21. Lam BYK, Cai Y, Akinyemi R, Biessels GJ, van den Brink H, Chen C, Cheung CW, Chow KN, Chung HKH, Duering M, et al. The global burden of cerebral small vessel disease in low- and middle-income countries: a systematic review and meta-analysis.Int J Stroke. 2023; 18:15–27. doi: 10.1177/17474930221137019CrossrefGoogle Scholar22. Vinters HV, Zarow C, Borys E, Whitman JD, Tung S, Ellis WG, Zheng L, Chui HC. Review: vascular dementia: clinicopathologic and genetic considerations.Neuropathol Appl Neurobiol. 2018; 44:247–266. doi: 10.1111/nan.12472CrossrefGoogle Scholar23. Alkayed NJ, Cipolla MJ. The ever-evolving concept of the neurovascular unit.Stroke. 2023; 54:2178–2180. doi: 10.1161/STROKEAHA.123.042705LinkGoogle Scholar24. Markus HS, de Leeuw FE. Cerebral small vessel disease: recent advances and future directions.Int J Stroke. 2023; 18:4–14. doi: 10.1177/17474930221144911CrossrefGoogle Scholar25. Walsh J, Tozer DJ, Sari H, Hong YT, Drazyk A, Williams G, Shah NJ, O'Brien JT, Aigbirhio FI, Rosenberg G, et al. Microglial activation and blood-brain barrier permeability in cerebral small vessel disease.Brain. 2021; 144:1361–1371. doi: 10.1093/brain/awab003CrossrefMedlineGoogle Scholar26. Wang Z, Chen Q, Chen J, Yang N, Zheng K. Risk factors of cerebral small vessel disease: a systematic review and meta-analysis.Medicine (Baltim). 2021; 100:e28229. doi: 10.1097/MD.0000000000028229CrossrefGoogle Scholar27. Piao X, Wu G, Yang P, Shen J, De A, Wu J, Qu Q. Association between homocysteine and cerebral small vessel disease: a meta-analysis.J Stroke Cerebrovasc Dis. 2018; 27:2423–2430. doi: 10.1016/j.jstrokecerebrovasdis.2018.04.035CrossrefGoogle Scholar28. Kim EJ, Park CG, Park JS, Suh SY, Choi CU, Kim JW, Kim SH, Lim HE, Rha SW, Seo HS, et al. Relationship between blood pressure parameters and pulse wave velocity in normotensive and hypertensive subjects: invasive study.J Hum Hypertens. 2007; 21:141–148. doi: 10.1038/sj.jhh.1002120CrossrefMedlineGoogle Scholar29. Wardlaw JM, Doubal FN, Valdes-Hernandez M, Wang X, Chappell FM, Shuler K, Armitage PA, Carpenter TC, Dennis MS. Blood-brain barrier permeability and long-term clinical and imaging outcomes in cerebral small vessel disease.Stroke. 2013; 44:525–527. doi: 10.1161/STROKEAHA.112.669994LinkGoogle Scholar30. Bordes C, Sargurupremraj M, Mishra A, Debette S. Genetics of common cerebral small vessel disease.Nat Rev Neurol. 2022; 18:84–101. doi: 10.1038/s41582-021-00592-8CrossrefMedlineGoogle Scholar31. Tian Y, Zhao M, Chen Y, Yang M, Wang Y. Correction: Tian et al. The underlying role of the glymphatic system and meningeal lymphatic vessels in cerebral small vessel disease. Biomolecules 2022, 12, 748.Biomolecules. 2023; 13:705. doi: 10.3390/biom13040705CrossrefGoogle Scholar32. Silbert LC, Dodge HH, Perkins LG, Sherbakov L, Lahna D, Erten-Lyons D, Woltjer R, Shinto L, Kaye JA. Trajectory of white matter hyperintensity burden preceding mild cognitive impairment.Neurology. 2012; 79:741–747. doi: 10.1212/WNL.0b013e3182661f2bCrossrefMedlineGoogle Scholar33. Wardlaw JM, Smith EE, Biessels GJ, Cordonnier C, Fazekas F, Frayne R, Lindley RI, O'Brien JT, Barkhof F, Benavente OR, et al; STandards for ReportIng Vascular changes on nEuroimaging (STRIVE v1). Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration.Lancet Neurol. 2013; 12:822–838. doi: 10.1016/S1474-4422(13)70124-8CrossrefMedlineGoogle Scholar34. Duering M, Biessels GJ, Brodtmann A, Chen C, Cordonnier C, de Leeuw FE, Debette S, Frayne R, Jouvent E, Rost NS, et al. Neuroimaging standards for research into small vessel disease-advances since 2013.Lancet Neurol. 2023; 22:602–618. doi: 10.1016/S1474-4422(23)00131-XCrossrefMedlineGoogle Scholar35. Ko H, Lam BYK, Mok VCT. Pathophysiology of vascular cognitive impairment (ii): amyloid contribution in vascular cognitive impairment. In: Lee SH, Lim JS, eds. Stroke Revisited: Vascular Cognitive Impairment. Springer Singapore; 2020:87–97.Google Scholar36. Sweeney MD, Montagne A, Sagare AP, Nation DA, Schneider LS, Chui HC, Harrington MG, Pa J, Law M, Wang DJJ, et al. Vascular dysfunction-the disregarded partner of Alzheimer's disease.Alzheimers Dement. 2019; 15:158–167. doi: 10.1016/j.jalz.2018.07.222CrossrefMedlineGoogle Scholar37. Kapasi A, Yu L, Petyuk V, Arfanakis K, Bennett DA, Schneider JA. Association of small vessel disease with tau pathology.Acta Neuropathol. 2022; 143:349–362. doi: 10.1007/s00401-021-02397-xCrossrefGoogle Scholar38. Lee S, Viqar F, Zimmerman ME, Narkhede A, Tosto G, Benzinger TL, Marcus DS, Fagan AM, Goate A, Fox NC, et al; Dominantly Inherited Alzheimer Network. White matter hyperintensities are a core feature of Alzheimer's disease: evidence from the dominantly inherited Alzheimer network.Ann Neurol. 2016; 79:929–939. doi: 10.1002/ana.24647CrossrefMedlineGoogle Scholar39. Schilling S, DeStefano AL, Sachdev PS, Choi SH, Mather KA, DeCarli CD, Wen W, Høgh P, Raz N, Au R, et al. Apoe genotype and MRI markers of cerebrovascular disease: systematic review and meta-analysis.Neurology. 2013; 81:292–300. doi: 10.1212/WNL.0b013e31829bfda4CrossrefMedlineGoogle Scholar40. Gottesman RF, Schneider AL, Zhou Y, Coresh J, Green E, Gupta N, Knopman DS, Mintz A, Rahmim A, Sharrett AR, et al. Association between midlife vascular risk factors and estimated brain amyloid deposition.JAMA. 2017; 317:1443–1450. doi: 10.1001/jama.2017.3090CrossrefMedlineGoogle Scholar41. Toledo JB, Arnold SE, Raible K, Brettschneider J, Xie SX, Grossman M, Monsell SE, Kukull WA, Trojanowski JQ. Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer's Coordinating Centre.Brain. 2013; 136:2697–2706. doi: 10.1093/brain/awt188CrossrefMedlineGoogle Scholar42. Attems J, Jellinger KA. The overlap between vascular disease and Alzheimer's disease--lessons from pathology.BMC Med. 2014; 12:206. doi: 10.1186/s12916-014-0206-2CrossrefMedlineGoogle Scholar43. Azarpazhooh MR, Avan A, Cipriano LE, Munoz DG, Sposato LA, Hachinski V. Concomitant vascular and neurodegenerative pathologies double the risk of dementia.Alzheimers Dement. 2018; 14:148–156. doi: 10.1016/j.jalz.2017.07.755CrossrefMedlineGoogle Scholar44. Ip B, Au L, Chan A, Fan F, Ip V, Ma SH, Ma K, Mok V, Lau A, Leng X, et al. Evolving ischemic stroke subtypes in 15 years: a hospital-based observational study.Int J Stroke. 2022; 17:444–454. doi: 10.1177/17474930211005953CrossrefGoogle Scholar45. Wang Y, Zhao X, Liu L, Soo YO, Pu Y, Pan Y, Wang Y, Zou X, Leung TW, Cai Y, et al; CICAS Study Group. Prevalence and outcomes of symptomatic intracranial large artery stenoses and occlusions in China: the Chinese Intracranial Atherosclerosis (CICAS) Study.Stroke. 2014; 45:663–669. doi: 10.1161/STROKEAHA.113.003508LinkGoogle Scholar46. Bogiatzi C, Hackam DG, McLeod AI, Spence JD. Secular trends in ischemic stroke subtypes and stroke risk factors.Stroke. 2014; 45:3208–3213. doi: 10.1161/STROKEAHA.114.006536LinkGoogle Scholar47. Kempster PA, Gerraty RP, Gates PC. Asymptomatic cerebral infarction in patients with chronic atrial fibrillation.Stroke. 1988; 19:955–957. doi: 10.1161/01.str.19.8.955LinkGoogle Scholar48. Meinel TR, Kaesmacher J, Roten L, Fischer U. Covert brain infarction: towards precision medicine in research, diagnosis, and therapy for a silent pandemic.Stroke. 2020; 51:2597–2606. doi: 10.1161/STROKEAHA.120.030686LinkGoogle Scholar49. Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MM. Silent brain infarcts and the risk of dementia and cognitive decline.N Engl J Med. 2003; 348:1215–1222. doi: 10.1056/NEJMoa022066CrossrefMedlineGoogle Scholar50. Zheng L, Tian X, Abrigo J, Fang H, Ip BY, Liu Y, Li S, Liu Y, Lan L, Liu H, et al. Hemodynamic significance of intracranial atherosclerotic disease and ipsilateral imaging markers of cerebral small vessel disease.Eur Stroke J. 2024; 9:144–153. doi: 10.1177/23969873231205669CrossrefGoogle Scholar51. Marshall RS, Festa JR, Cheung YK, Chen R, Pavol MA, Derdeyn CP, Clarke WR, Videen TO, Grubb RL, Adams HP, et al. Cerebral hemodynamics and cognitive impairment: baseline data from the recon trial.Neurology. 2012; 78:250–255. doi: 10.1212/WNL.0b013e31824365d3CrossrefMedlineGoogle Scholar52. Balestrini S, Perozzi C, Altamura C, Vernieri F, Luzzi S, Bartolini M, Provinciali L, Silvestrini M. Severe carotid stenosis and impaired cerebral hemodynamics can influence cognitive deterioration.Neurology. 2013; 80:2145–2150. doi: 10.1212/WNL.0b013e318295d71aCrossrefMedlineGoogle Scholar53. Ni L, Zhou F, Qing Z, Zhang X, Li M, Zhu B, Zhang B, Xu Y. The asymmetry of white matter hyperintensity burden between hemispheres is associated with intracranial atherosclerotic plaque enhancement grade.Front Aging Neurosci. 2020; 12:163. doi: 10.3389/fnagi.2020.00163CrossrefGoogle Scholar54. Feng F, Kan W, Yang H, Ding H, Wang X, Dong R. White matter hyperintensities had a correlation with the cerebral perfusion level, but no correlation with the severity of large vessel stenosis in the anterior circulation.Brain Behav. 2023; 13:e2932. doi: 10.1002/brb3.2932CrossrefGoogle Scholar55. Lv B, Tian C. Asymmetrically dilated perivascular space and impaired perfusion in bilateral middle cerebral artery occlusion.Stroke. 2023; 54:e421–e422. doi: 10.1161/STROKEAHA.123.043663LinkGoogle Scholar56. Gupta A, Iadecola C. Impaired aβ clearance: a potential link between atherosclerosis and Alzheimer's disease.Front Aging Neurosci. 2015; 7:115. doi: 10.3389/fnagi.2015.00115CrossrefMedlineGoogle Scholar57. Roher AE, Esh CL, Kokjohn TA, Castaño EM, Van Vickle GD, Kalback WM, Patton RL, Luehrs DC, Daugs ID, Kuo YM, et al. Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer's disease.Alzheimers Dement. 2009; 5:18–29. doi: 10.1016/j.jalz.2008.10.004CrossrefMedlineGoogle Scholar58. Yarchoan M, Xie SX, Kling MA, Toledo JB, Wolk DA, Lee EB, Van Deerlin V, Lee VM, Trojanowski JQ, Arnold SE. Cerebrovascular atherosclerosis correlates with Alzheimer pathology in neurodegenerative dementias.Brain. 2012; 135:3749–3756. doi: 10.1093/brain/aws271CrossrefMedlineGoogle Scholar59. Alosco ML, Brickman AM, Spitznagel MB, Garcia SL, Narkhede A, Griffith EY, Raz N, Cohen R, Sweet LH, Colbert LH, et al. Cerebral perfusion is associated with white matter hyperintensities in older adults with heart failure.Congest Heart Fail. 2013; 19:E29–E34. doi: 10.1111/chf.12025CrossrefMedlineGoogle Scholar60. Dichgans M, Leys D. Vascular cognitive impairment.Circ Res. 2017; 120:573–591. doi: 10.1161/CIRCRESAHA.116.308426LinkGoogle Scholar61. Graff-Radford J, Madhavan M, Vemuri P, Rabinstein AA, Cha RH, Mielke MM, Kantarci K, Lowe V, Senjem ML, Gunter JL, et al. Atrial fibrillation, cognitive impairment, and neuroimaging.Alzheimers Dement. 2016; 12:391–398. doi: 10.1016/j.jalz.2015.08.164CrossrefMedlineGoogle Scholar62. Quinn TJ, Gallacher J, Deary IJ, Lowe GD, Fenton C, Stott DJ. Association between circulating hemostatic measures and dementia or cognitive impairment: systematic review and meta-analyzes.J Thromb Haemost. 2011; 9:1475–1482. doi: 10.1111/j.1538-7836.2011.04403.xCrossrefMedlineGoogle Scholar63. Rivard L, Friberg L, Conen D, Healey JS, Berge T, Boriani G, Brandes A, Calkins H, Camm AJ, Yee Chen L, et al. Atrial fibrillation and dementia: a report from the AF-screen international collaboration.Circulation. 2022; 145:392–409. doi: 10.1161/CIRCULATIONAHA.121.055018LinkGoogle Scholar64. Wu YT, Beiser AS, Breteler MMB, Fratiglioni L, Helmer C, Hendrie HC, Honda H, Ikram MA, Langa KM, Lobo A, et al. The changing prevalence and incidence of dementia over time - current evidence.Nat Rev Neurol. 2017; 13:327–339. doi: 10.1038/nrneurol.2017.63CrossrefMedlineGoogle Scholar65. Satizabal CL, Beiser AS, Chouraki V, Chêne G, Dufouil C, Seshadri S. Incidence of dementia over three decades in the Framingham Heart Study.N Engl J Med. 2016; 374:523–532. doi: 10.1056/NEJMoa1504327CrossrefMedlineGoogle Scholar66. Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, Wessels AM, Shcherbinin S, Wang H, Monkul Nery ES, et al; TRAILBLAZER-ALZ 2 Investigators. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial.JAMA. 2023; 330:512–527. doi: 10.1001/jama.2023.13239CrossrefGoogle Scholar67. van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, Kanekiyo M, Li D, Reyderman L, Cohen S, et al. Lecanemab in early Alzheimer's disease.N Engl J Med. 2023; 388:9–21. doi: 10.1056/NEJMoa2212948CrossrefGoogle Scholar68. Kleindorfer DO, Towfighi A, Chaturvedi S, Cockroft KM, Gutierrez J, Lombardi-Hill D